Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The deep learning model provides a noninvasive method to predict high PD-L1 expression of NSCLC and to infer clinical outcomes in response to immunotherapy. Additionally, this deep learning model combined with clinical models demonstrated improved stratification capabilities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Given the overall response rates to ICI treatment, ranging from 14% to 20% in unselected patients [3,4], it is essential to identify predictive biomarkers for the selection of patients who are more likely to respond to immunotherapy.”
BackgroundiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · cited 1×
“PFS was obtained using iRECIST criteria, which is the response criteria used in trials testing immunotherapeutic [27].”
MethodSpranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · cited 1×
“Alternatively, it can be induced in response to immune-stimulating cytokines, such as interferons, that are produced by an active antitumor immune response [7,8].”
BackgroundReck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670 · cited 1×
“In the first-line setting, pembrolizumab monotherapy demonstrated improved progression-free survival (PFS) and overall survival (OS) benefit compared to chemotherapy in NSCLC patients with PD‐L1 expression on ≥ 50% of tumor cells (KEYNOTE 024) [9,11].”
BackgroundSun, R., Limkin, E. J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S. R., Verlingue, L., Brandao, D., Lancia, A., Ammari, S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30413-3 · Cited by 1,236 · cited 1×
“Sun and colleagues evaluated the association between a radiomics-based biomarker of tumor-infiltrating CD8 cells and clinical outcomes of anti-PD-1 and PD-L1 treatment [36].”
BackgroundThe Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review
Aerts, H. J. W. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2631 · Cited by 669
Defining the biological basis of radiomic phenotypes in lung cancer
Grossmann, P., Stringfield, O., El-Hachem, N., Bui, M. M., Rios Velazquez, E., Parmar, C., Leijenaar, R. T., Haibe-Kains, B., Lambin, P., Gillies, R. J., et al. (2017) · eLife · doi:10.7554/elife.23421 · Cited by 365
Khorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P. D., Thawani, R., Corredor, G., Alilou, M., Bera, K., Fu, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0476 · Cited by 297 · cited 1×
“Radiomics is the science of quantifying patterns of tumor phenotypes on radiographic images in a high throughput manner and analyzing them with bioinformatics tools to build clinically relevant models that assess tumor and microenvironment heterogeneity [19].”
Background
Cited by
Swanson, K., Wu, E., Zhang, A., Alizadeh, A. A., & Zou, J. (2023) · Cell · doi:10.1016/j.cell.2023.01.035 · Cited by 597
“57 This enables a non-invasive prediction of response to anti-PD-1 antibody immunotherapy.”
BackgroundDeep Learning for Medical Image-Based Cancer Diagnosis
Jiang, X., Hu, Z., Wang, S., & Zhang, Y. (2023) · Cancers · doi:10.3390/cancers15143608 · Cited by 345
Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.125 · Cited by 340
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
The artificial intelligence and machine learning in lung cancer immunotherapy
Gao, Q., Yang, L., Lu, M., Jin, R., Ye, H., & Ma, T. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01456-y · Cited by 148
Metadata
- Authors
- Tian, P., He, B., Mu, W., Liu, K., Liu, L., Zeng, H., Liu, Y., Jiang, L., Zhou, P., Huang, Z., Dong, D., & Li, W.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 5
- Pages
- 2098-2107
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3110954991
- Cited by
- 155
- References
- 9
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. https://app.cochat.ai/papers/10.7150/thno.48027
- The paper
- Tian, P., He, B., Mu, W., Liu, K., Liu, L., Zeng, H., Liu, Y., Jiang, L., Zhou, P., Huang, Z., Dong, D., & Li, W. (2021). Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. https://doi.org/10.7150/thno.48027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.